Verition Fund Management
VIR icon

Verition Fund Management’s Vir Biotechnology VIR Stock Holding History

Verition Fund Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-59,670
Closed -$301K – 4010
2025
Q2 		$301K Buy
+59,670
New +$320K ﹤0.01% 3201
2025
Q1 		– Sell
-145,873
Closed -$1.07M – 3744
2024
Q4 		$1.07M Buy
145,873
+93,079
+176% +$734K ﹤0.01% 2000
2024
Q3 		$395K Buy
+52,794
New +$459K ﹤0.01% 2465
2024
Q2 		– Sell
-11,714
Closed -$119K – 3278
2024
Q1 		$119K Buy
+11,714
New +$119K ﹤0.01% 2564
2022
Q4 		– Sell
-16,646
Closed -$321K – 2776
2022
Q3 		$321K Buy
+16,646
New +$423K ﹤0.01% 2176
2022
Q2 		– Sell
-14,090
Closed -$362K – 3086
2022
Q1 		$362K Buy
14,090
+5,901
+72% +$175K ﹤0.01% 2073
2021
Q4 		$343K Buy
+8,189
New +$321K ﹤0.01% 1919
2020
Q3 		– Sell
-40,536
Closed -$1.66M – 1388
2020
Q2 		$1.66M Buy
+40,536
New +$1.36M 0.05% 269

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verition Fund Management's VIR Position: Q3 2025 in Review

Verition Fund Management sold out of Vir Biotechnology (VIR) in Q3 2025, closing a stake of 59,670 shares — an estimated $301K sold.

Verition Fund Management first reported a position in VIR in Q2 2020 and held it in 8 quarters. The position peaked at $1.66M in Q2 2020. 213 funds tracked by Wall St. Rank hold VIR as of Q3 2025.

  • Verition Fund Management reported no remaining Vir Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 59,670 Vir Biotechnology shares in Q3 2025, an estimated $301K.
  • Verition Fund Management first reported a position in Vir Biotechnology in Q2 2020 and held it in 8 quarters.
  • Verition Fund Management's Vir Biotechnology position peaked at $1.66M in Q2 2020.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.